| Literature DB >> 17694296 |
N Y Souren1, A D C Paulussen, R J F Loos, M Gielen, G Beunen, R Fagard, C Derom, R Vlietinck, M P Zeegers.
Abstract
AIMS/HYPOTHESIS: We determined the genetic contribution of 18 anthropometric and metabolic risk factors of type 2 diabetes using a young healthy twin population.Entities:
Mesh:
Substances:
Year: 2007 PMID: 17694296 PMCID: PMC2039867 DOI: 10.1007/s00125-007-0784-z
Source DB: PubMed Journal: Diabetologia ISSN: 0012-186X Impact factor: 10.122
Fig. 1Path diagram for a univariate quantitative heterogeneity (a), scalar (b) and homogeneity (c) model only presenting opposite sex pairs. Observed phenotypes (PM and PW) for the male and female twins are shown in rectangles, while latent factors (A, C and E) and latent phenotypes (LPM and LPW) are shown in circles. Path coefficients of observed variables on the different latent factors are shown in lower case: a, additive genetic effect; c, common environmental effect; e, unique environmental effect; k, scalar factor. The genetic correlation is represented by rg (1 for MZ and 0.5 for DZ twins) and the common environmental correlation is represented by rc (1 for MZ and DZ twins)
Anthropometric and metabolic characteristics of the twin population according to chorion type for men and women separately in the EFPTS
| Characteristic | Men | Women | ||||||
|---|---|---|---|---|---|---|---|---|
| MZ MC | MZ DC | DZ | MZ MC | MZ DC | DZ | |||
| 134 | 92 | 135 | 142 | 112 | 141 | |||
| Age (years)a | 25.3 ± 4.5 | 25.0 ± 4.9 | 25.7 ± 4.7 | 0.33 | 25.9 ± 4.4 | 24.0 ± 4.8 | 25.7 ± 4.6 | 0.02 |
| Body height (cm) | 178.0 ± 5.7 | 178.3 ± 7.2 | 178.4 ± 6.5 | 0.92 | 165.0 ± 6.3 | 165.6 ± 6.1 | 166.2 ± 6.4 | 0.59 |
| Body mass (kg) | 70.7 ± 10.5 | 69.6 ± 8.4 | 70.9 ± 10.2 | 0.67 | 60.5 ± 9.7 | 60.5 ± 10.6 | 60.8 ± 10.2 | 0.98 |
| BMI (kg/m2) | 22.1 ± 1.1 | 21.8 ± 1.1 | 22.1 ± 1.2 | 0.73 | 22.0 ± 1.2 | 21.8 ± 1.2 | 21.8 ± 1.2 | 0.86 |
| WHR (%) | 83.4 ± 5.4 | 83.4 ± 5.8 | 82.8 ± 5.5 | 0.84 | 73.4 ± 4.5 | 73.3 ± 4.6 | 72.5 ± 4.3 | 0.30 |
| S4SF (mm)b | 35.9 ± 1.5 | 34.6 ± 1.5 | 34.8 ± 1.5 | 0.89 | 57.1 ± 1.4 | 55.6 ± 1.5 | 53.6 ± 1.4 | 0.50 |
| Fat mass (kg)b | 11.9 ± 1.6 | 11.2 ± 1.5 | 12.2 ± 1.5 | 0.33 | 16.9 ± 1.3 | 16.7 ± 1.4 | 16.8 ± 1.3 | 0.95 |
| Lean body mass (kg) | 57.7 ± 6.9 | 57.6 ± 6.0 | 57.7 ± 6.6 | 0.99 | 42.9 ± 5.1 | 43.1 ± 5.6 | 43.4 ± 6.0 | 0.89 |
| IGFBP-1 (ng/ml)b | 11.0 ± 1.9 | 10.3 ± 1.8 | 11.5 ± 1.9 | 0.46 | 16.8 ± 2.0 | 16.6 ± 2.2 | 18.4 ± 2.3 | 0.58 |
| Fasting insulin (pmol/l)b | 33.5 ± 1.5 | 32.7 ± 1.6 | 32.7 ± 1.6 | 0.94 | 38.6 ± 1.5 | 35.8 ± 1.6 | 40.1 ± 1.5 | 0.24 |
| Insulin resistance (HOMA)b | 1.2 ± 1.6 | 1.2 ± 1.6 | 1.2 ± 1.6 | 0.69 | 1.3 ± 1.5 | 1.2 ± 1.7 | 1.4 ± 1.5 | 0.26 |
| Fasting glucose (mmol/l) | 5.0 ± 0.5 | 4.9 ± 0.4 | 4.8 ± 0.4 | 0.01 | 4.5 ± 0.3 | 4.6 ± 0.4 | 4.6 ± 0.4 | 0.23 |
| Beta cell function (HOMA)b | 77.2 ± 1.5 | 78.2 ± 1.6 | 86.5 ± 1.7 | 0.10 | 135.2 ± 1.7 | 115.7 ± 1.6 | 126.7 ± 1.6 | 0.17 |
| Leptin (ng/ml)b | 1.7 ± 3.0 | 1.4 ± 2.9 | 1.7 ± 3.0 | 0.42 | 11.5 ± 2.1 | 11.2 ± 2.2 | 11.5 ± 1.9 | 0.92 |
| Total cholesterol (mmol/l) | 4.8 ± 0.9 | 4.7 ± 1.0 | 4.9 ± 1.1 | 0.31 | 5.3 ± 0.9 | 4.9 ± 0.8 | 5.3 ± 1.0 | 0.006 |
| LDL-cholesterol (mmol/l) | 3.0 ± 0.9 | 2.9 ± 0.9 | 3.1 ± 1.0 | 0.35 | 3.1 ± 0.8 | 2.7 ± 0.8 | 2.9 ± 0.8 | 0.012 |
| HDL-cholesterol (mmol/l) | 1.3 ± 0.3 | 1.3 ± 0.3 | 1.4 ± 0.4 | 0.94 | 1.8 ± 0.4 | 1.8 ± 0.4 | 1.9 ± 0.4 | 0.39 |
| Total cholesterol:HDL-cholesterol ratiob | 3.6 ± 1.4 | 3.5 ± 1.3 | 3.7 ± 1.4 | 0.67 | 3.0 ± 1.3 | 2.8 ± 1.3 | 2.9 ± 1.3 | 0.34 |
| Triacylglycerol (mmol/l)b | 0.9 ± 1.6 | 0.9 ± 1.5 | 0.9 ± 1.5 | 0.78 | 0.9 ± 1.5 | 0.9 ± 1.5 | 0.9 ± 1.5 | 0.83 |
| NEFA (mmol/l) | 0.5 ± 0.2 | 0.5 ± 0.2 | 0.5 ± 0.2 | 0.05 | 0.7 ± 0.2 | 0.7 ± 0.3 | 0.7 ± 0.2 | 0.81 |
Data are expressed as mean ± SD
HOMA, homeostasis model assessment
ap value calculated using standard linear regression, because convergence criteria could not be met using a random intercept model
bGeometric mean ± SD
Intra-pair correlations of MZ MC and MZ DC pairs, and of each sex by zygosity group before and after adjusting for covariates in the EFPTS
| Characteristic | Monozygotic | Monozygotic | Dizygotic | Covariates | ||||
|---|---|---|---|---|---|---|---|---|
| MC | DC | Men | Women | Men | Women | OS | ||
| 138 | 102 | 113 | 127 | 46 | 49 | 43 | ||
| Body mass | 0.85/0.79 | 0.84/0.76 | 0.86/0.82 | 0.76/0.73 | 0.38/0.28 | 0.58/0.57 | 0.26/0.35 | Sex, age, height |
| BMI | 0.80/0.78 | 0.81/0.77 | 0.86/0.83 | 0.77/0.74 | 0.46/0.31 | 0.53/0.56 | 0.47/0.46 | Age |
| WHR | 0.87/0.69 | 0.88/0.71 | 0.79/0.74 | 0.70/0.66 | 0.39/0.28 | 0.44/0.48 | 0.31/0.15 | Sex, age |
| S4SF | 0.82/0.73 | 0.84/0.75 | 0.81/0.79 | 0.72/0.68 | 0.46/0.37 | 0.64/0.63 | 0.36/0.31 | Sex, age |
| Fat mass | 0.85/0.78 | 0.85/0.75 | 0.85/0.82 | 0.73/0.69 | 0.46/0.36 | 0.43/0.46 | 0.42/0.35 | Sex, age |
| Lean body mass | 0.93/0.81 | 0.93/0.79 | 0.86/0.82 | 0.79/0.78 | 0.43/0.39 | 0.65/0.58 | 0.25/0.39 | Sex, age, height |
| IGFBP-1 | 0.49/0.39 | 0.60/0.53 | 0.55/0.51 | 0.45/0.43 | 0.31/0.21 | 0.08/0.06 | 0.12/−0.05 | Sex, age, BMI |
| Fasting insulin | 0.57/0.48 | 0.52/0.50 | 0.49/0.45 | 0.58/0.52 | 0.07/0.13 | 0.18/0.19 | 0.07/−0.01 | Age, S4SF |
| Insulin resistance | 0.54/0.47 | 0.53/0.50 | 0.49/0.46 | 0.57/0.51 | 0.03/0.08 | 0.14/0.17 | 0.04/−0.05 | Sex, age, S4SF |
| Fasting glucose | 0.74/0.66 | 0.73/0.67 | 0.65/0.65 | 0.70/0.69 | 0.28/0.24 | 0.57/0.60 | 0.31/0.32 | Sex, BMI |
| Beta cell function | 0.71/0.58 | 0.66/0.60 | 0.52/0.50 | 0.68/0.66 | 0.32/0.40 | 0.47/0.46 | 0.37/0.33 | Sex, age, S4SF |
| Leptin | 0.85/0.53 | 0.85/0.57 | 0.70/0.58 | 0.64/0.52 | 0.35/0.02 | 0.66/0.31 | 0.38/0.37 | Sex, age, S4SF |
| Total cholesterol | 0.76/0.74 | 0.77/0.72 | 0.78/0.74 | 0.73/0.73 | 0.52/0.51 | 0.51/0.44 | 0.63/0.51 | Age, S4SF |
| LDL-cholesterol | 0.78/0.79 | 0.81/0.74 | 0.81/0.79 | 0.77/0.75 | 0.52/0.51 | 0.59/0.52 | 0.68/0.58 | Sex, age, S4SF |
| HDL-cholesterol | 0.78/0.71 | 0.84/0.77 | 0.75/0.76 | 0.74/0.74 | 0.31/0.30 | 0.44/0.44 | 0.52/0.52 | Sex, S4SF |
| Total cholesterol:HDL-cholesterol ratio | 0.81/0.78 | 0.86/0.81 | 0.84/0.82 | 0.78/0.76 | 0.50/0.41 | 0.50/0.49 | 0.65/0.54 | Age, WHR |
| Triacylglycerol | 0.58/0.56 | 0.67/0.60 | 0.59/0.54 | 0.63/0.60 | 0.29/0.41 | 0.34/0.34 | 0.16/0.17 | Sex, S4SF |
| NEFA | 0.49/0.35 | 0.43/0.39 | 0.39/0.38 | 0.34/0.37 | 0.10/0.14 | 0.20/0.18 | 0.25/0.26 | Sex, S4SF |
Values are unadjusted intra-pair correlation/adjusted intra-pair correlation.
OS, opposite sex
Variance components estimates and 95% CIs of best-fitting models expressed in percentages
| Characteristic | Unadjusted | Adjusted for covariates | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Model | Sex | a2 (H2) | c2 | d2 (H2) | e2 | S | Model | Sex | a2 (H2) | c2 | d2 (H2) | e2 | S | |
| Body mass | AE | M | 90 (86–93) | – | – | 10 (7–14) | AE | M | 84 (78–88) | – | – | 16 (12–22) | ||
| AE | W | 80 (73–85) | – | – | 20 (15–27) | AE | W | 74 (66–80) | – | – | 26 (20–34) | |||
| BMI | AE | M | 87 (82–90) | – | – | 13 (10–18) | AE | M | 85 (79–89) | – | – | 15 (11–21) | ||
| AE | W | 76 (68–82) | – | – | 24 (18–32) | AE | W | 75 (67–81) | – | – | 25 (19–33) | |||
| WHR | AE | M | 94 (92–96) | – | – | 6 (4–8) | AE | 70 (63–75) | – | – | 30 (25–37) | M>W | ||
| AE | W | 70 (59–77) | – | – | 30 (23–41) | |||||||||
| S4SF | AE | M | 88 (83–91) | – | – | 12 (9–17) | AE | 74 (68–79) | – | – | 26 (21–32) | M>W | ||
| AE | W | 75 (67–81) | – | – | 25 (19–33) | |||||||||
| Fat mass | AE | M | 88 (84–92) | – | – | 12 (8–16) | AE | M | 81 (74–86) | – | – | 19 (14–26) | ||
| AE | W | 74 (65–80) | – | – | 26 (20–35) | AE | W | 70 (60–77) | – | – | 30 (23–40) | |||
| Lean body mass | AE | M | 97 (96–98) | – | – | 3 (2–4) | AE | 81 (76–84) | – | – | 19 (16–24) | M>W | ||
| AE | W | 82 (76–87) | – | – | 18 (13–24) | |||||||||
| IGFBP-1 | DE | – | – | 56 (47–64) | 44 (36–53) | W>M | DE | – | – | 47 (36–56) | 53 (44–64) | W>M | ||
| Fasting insulin | DE | – | – | 54 (45–62) | 46 (38–55) | DE | – | – | 49 (39–58) | 51 (42–61) | ||||
| Insulin resistance | DE | – | – | 52 (42–60) | 48 (40–58) | DE | – | – | 48 (38–57) | 52 (43–62) | ||||
| Fasting glucose | AE | 72 (66–77) | – | – | 28 (23–34) | M>W | AE | 67 (60–73) | – | – | 33 (27–40) | M>W | ||
| Beta cell function | AE | 69 (63–75) | – | – | 31 (25–37) | AE | 62 (54–69) | – | – | 38 (31–46) | ||||
| Leptin | AE | M | 92 (88–94) | – | – | 8 (6–12) | AE | 53 (44–61) | – | – | 47 (39–56) | M>W | ||
| AE | W | 63 (52–72) | – | – | 37 (28–48) | |||||||||
| Total cholesterol | ACE | 49 (28–74) | 29 (4–48) | – | 22 (18–28) | AE | 75 (69–79) | – | – | 25 (21–31) | ||||
| LDL-cholesterol | ACE | 43 (24–67) | 37 (14–54) | – | 20 (16–25) | M>W | AE | 78 (73–82) | – | – | 22 (18–27) | |||
| HDL-cholesterol | AE | 82 (78–86) | – | – | 18 (14–22) | W>M | AE | 76 (70–81) | – | – | 24 (19–30) | W>M | ||
| Total cholesterol:HDL-cholesterol ratio | AE | M | 88 (83–91) | – | – | 12 (9–17) | AE | 79 (74–83) | – | – | 21 (17–26) | M>W | ||
| AE | W | 79 (72–85) | – | – | 21 (15–28) | |||||||||
| Triacylglycerol | AE | 61 (52–68) | – | – | 39 (32–48) | AE | 58 (49–66) | – | – | 42 (34–51) | ||||
| NEFA | AE | 46 (36–54) | – | – | 54 (46–64) | W>M | AE | 37 (25–47) | – | – | 63 (53–75) | W>M | ||
Values are variance components estimates (95% CI)
M, men; W, women; a2, additive genetic variance; c2, common environmental variance; d2, non-additive genetic variance; e2, unique environmental variance; S, scalar effect; H2, broad heritability